Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
    Ge Zheng
Updated on 15 May 2022
granulocyte colony stimulating factor
colony stimulating factor


Rencent years have witnessed great progress of the treatment of acute myeloid leukemia. However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine)/IA(Idarubicin, cytarabine) chemotherapy, espiecially for the older patients and those not eligiable for receiving allo-HSCT. Azacitidine (AZA) was listed to methylation of drugs in China in 2018, is currently the only one approved methylation drugs in the treatment of AML(acute myeloid leukemia), in the NCCN guidelines. The homoharringtonie could induce AML(acute myeloid leukemia) cell lines and primary myeloid leukemia cell apoptosis, and the effect was dose dependent. While, HHT could also induce leukemia cells to differentiate into normal state, eventually achieve the goal of treatment, and control the disease. The investigators conducted a clinical study to evaluate the efficacy and safety of the AZA plus HAG(homoharringtonie, cytarabine, G-CSF), HIA(homoharringtonie, Idarubicin, cytarabine)/HDA(homoharringtonie, daunorubicin, cytarabine). This study is aimed to validate the efficacy and safety advantages of the regimens that cotain homoharringtonie and azacitidine, and to determine which regimen would receive more living benefits.


Currently, the treatment of acute myeloid leukemia still remains a therapeutic challenge. Patients received traditional chemotherapy have a low remission rate, poor prognosis and short survival period for patients. New treatment strategies are needed in find out a better chemotherapy regimen.

Azacitidine (AZA) was listed to methylation of drugs in China in 2018, is currently the only approved drug for use in acute myeloid leukemia to methylation of drugs, in the NCCN guidelines. New combinations based on the azacitidine are currently undergoing, and the preliminary results brought new hope to the treatment of AML.

The homoharringtonie was extracted from tricuspid plants of China. As a protein synthesis inhibitor, homoharringtonie plays a major role in the G1 / G2 phase in cells. In addition, it could induce AML cell lines and primary myeloid leukemia cell apoptosis, and the effect was dose dependent. Meanwhile it could also induce leukemia cells to differentiate into normal state, eventually controlled the progression of the disease.

Combination with azacitidine may become a new option.This study intends to apply azacitidine in combination with homoharringtonie for treating AML patients, aiming to improve the efficacy, reducing adverse reactions and improve the living qualities of patients.

Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.

Patients of denovo or relapsed AML(age<60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) or AZA+HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.

The investigators choose historical AML patients receiving tranditional chemotherapy as a control group, to validate the efficacy and safety profiles.

Condition Acute Myeloid Leukemia
Treatment Azacitidine, Homoharringtonine
Clinical Study IdentifierNCT04248595
SponsorGe Zheng
Last Modified on15 May 2022


Yes No Not Sure

Inclusion Criteria

Diagnoised with acute myeloid leukemia
Meet the criteria of the 2016 WHO classification system(APL were excluded), based on blood cell counting, bone marrow biopsy, and cytogeneic diagnosis
Volunteered to sign the informed consent

Exclusion Criteria

Mental disorders or other conditions that cannot meet the requirements of research, treatment and monitoring
Uncontrolled cardiovascular disease
Allergic to azacytarine, homoharringtonie, or other drugs of this study
Any other conditions considered by the study investgators that are not suitable for participating in this clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note